Evidence map›Paper›PMID 42295572›Full record

ArticleEJNMMI physics2026

A deep learning framework for lesion-level treatment response prediction in hodgkin lymphoma using PET/CT tensor radiomics.

Mahdie Jajroudi, Hossein Jamalirad, Milad Enferadi, Vahid Roshanravan, Farshad Emami, Parham Geramifar, Saeid Eslami

Abstract read
In one paragraph

Article in EJNMMI physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mahdie JajroudiPharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Hossein JamaliradDepartment of Medical Informatics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Milad EnferadiDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, 06520-8042, USA.
Vahid RoshanravanNuclear Medicine Research Center, Mashhad University of Medical Sciences, Ghaem Hospital, Mashhad, Iran.
Farshad EmamiNuclear Medicine and Molecular Imaging Department, Imam Reza International University, Razavi Hospital, Mashhad, Iran.
Parham GeramifarResearch Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran. pgeramifar@sina.tums.ac.ir.ORCID http://orcid.org/0000-0002-7607-6859
Saeid EslamiPharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. EslamiS@mums.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccurate prediction of treatment response in Hodgkin lymphoma (HL) is crucial for personalized therapy. The Tensor Radiomics (TR) paradigm advances traditional radiomics by producing and analyzing diverse feature variations, employing tensors computed across multiple parameter combinations to optimize radiomics feature extraction and improve tumor characterization. However, the complexity and variability of these features pose significant challenges for analysis and clinical application in HL research. This study introduces the Tensor Radiomics Network (TR-NET), a deep learning framework that automates feature selection from tensor radiomics data and predicts treatment response. It also incorporates explainable AI techniques to identify the most influential features.

methodsWe analyzed 420 lesions from 70 HL patients using

resultsTR-NET achieved a predictive performance, with an AUC-ROC of 0.8470 (95% CI: 0.7669-0.9185), a sensitivity of 82.2%, and a specificity of 78.2%, offering a balanced classification characteristic. In comparison, XGBoost achieved an AUC of 0.8160 (95% CI: 0.7457-0.8599), characterized by high sensitivity (93.3%) but lower specificity (66.2%), indicating a tendency towards false positives. Random Forest and SVM also showed high sensitivity (92% and 91.1%), but both suffered from significantly reduced specificity (29.5% and 51.3%).

conclusionTR-NET demonstrates enhanced predictive accuracy and clinical relevance compared to classic machine learning, supporting personalized treatment strategies and the integration of explainable AI in oncology.

Indexed as

Deep learningHodgkin lymphomaPET/CTTensor radiomicsTreatment response prediction

Identifiers

PMID42295572
PMCPMC13269603

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.